• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Crawley, C R
    Foran, J M
    Gupta, R K
    Rohatiner, A Z
    Summers, K
    Matthews, J
    Micallef, I N
    Radford, John A
    Johnson, Stephen A
    Johnson, Peter W
    Sweetenham, J W
    Lister, T Andrew
    Show allShow less
    Affiliation
    Department of Medical Oncology, St. Bartholomew's Hospital, London, UK.
    Issue Date
    2000-07
    
    Metadata
    Show full item record
    Abstract
    BACKGROUND: 'Molecular response' is being investigated as a therapeutic goal in follicular lymphoma (FL). High response rates in FL with the fludarabine combination 'FMD' have been associated with 'molecular remission'. A phase II study of FMD in FL was therefore conducted. PATIENTS AND METHODS: Fifty-four patients, ten of whom were newly diagnosed received FMD. Forty-four percent of the previously treated patients had 'chemoresistant' disease. Treatment comprised: fludarabine 25 mg/m2 days 1-3, mitoxantrone 10 mg/m2 day 1, and dexamethasone 20 mg days 1-5. Blood/bone marrow was collected for quantitation of t(14;18) by 'real-time' PCR. RESULTS: The overall response rate was 37 of 54 (69%), complete responses being seen in 11 patients (20%), with no difference between newly diagnosed and the previously treated patients. However, the response rate in 'chemosensitive' relapse was 84% compared to 44% in patients in whom the last prior regimen had failed. Molecular responses were seen in 17 of 25 and PCR negativity in 8 of 25, although molecular and clinical responses did not always correlate. Toxicity was moderate, 19 patients required admission. However, in 6 of 12 patients, subsequent G-CSF mobilised stem cell harvests failed. CONCLUSIONS: FMD was well tolerated but with a lower than expected response rate. Molecular responses were seen in the majority of responding patients however, 'molecular remission' was rare.
    Citation
    A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. 2000, 11 (7):861-5 Ann. Oncol.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/86440
    PubMed ID
    10997815
    Type
    Article
    Language
    en
    ISSN
    0923-7534
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    • Authors: Wilder DD, Ogden JL, Jain VK
    • Issue date: 2002 Mar
    • The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
    • Authors: Bishton MJ, Rule S, Wilson W, Turner D, Patmore R, Clifton-Hadley L, McMillan A, Lush R, Haynes A
    • Issue date: 2020 Aug
    • Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
    • Authors: Santini G, Chisesi T, Nati S, Porcellini A, Zoli V, Rizzoli V, Zupo S, Marino G, Rubagotti A, Polacco A, Spriano M, Vimercati R, Congiu AM, Ravetti JL, Aversa S, Candela M, Patti C
    • Issue date: 2004 Jun
    • Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
    • Authors: Zinzani PL, Pellegrini C, Broccoli A, Casadei B, Argnani L, Pileri S
    • Issue date: 2013 Nov
    • Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.
    • Authors: McLaughlin P, Hagemeister FB, Swan F Jr, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M
    • Issue date: 1994 Mar
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.